A recent drug-industry funded study in Health Affairs Scholar found that increased utilization, rather than rising drug prices, drives 340B program growth.
Drug-Industry Funded Study Finds Utilization Drives 340B Program Growth, Not Rising Drug Prices
A recent drug-industry-funded study attributes the 340B program’s recent growth to increased utilization—not rising drug prices. The May 21 study, [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
